



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

Final conference

EMCDDA–IPA5 project

Further preparation of the IPA Beneficiaries for their participation in the work of the EMCDDA

21 June 2017

Sarajevo, Bosnia and Herzegovina

Final conference of the EMCDDA-IPA5 project

The EMCDDA-IPA5 Final Conference is organised with the support of the Ministry of Security of Bosnia and Herzegovina and is taking place in Sarajevo, on 21 June 2017.

Meeting Venue:

Hotel Europe Sarajevo
V. Skarića 5, 71000 Sarajevo

Social event (20 June, 20.30)
Hotel Europe Sarajevo
V. Skarića 5, 71000 Sarajevo

The meeting is funded by the EMCDDA-IPA5 project 'Further preparation of the IPA beneficiaries for their participation in the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).'

Tuesday 20 June 2017

20.30	Social event
-------	--------------

Wednesday 21 June 2017

08.30	Registration of participants
09.00	<p>Plenary session I: Welcome and introduction</p> <p>Opening session: Mijo Krešić (Deputy Minister of Security Bosnia and Herzegovina) Richard Wood (Senior Adviser and Head of Rule of Law Section, Delegation of the European Union to Bosnia and Herzegovina) Cecile Martel (Head of International cooperation sector, EMCDDA)</p> <p>Main objectives of the EMCDDA-IPA5 project and key achievements</p>
09.30	<p>Plenary session II: Fostering scientific cooperation on data collection, analysis and interpretation – Drug seizures and emergence of new psychoactive substances</p> <p>Collection, analysis and appraisal of drug seizures data from the candidate and potential candidate countries to the European Union – overall project results — Brian Taylor (External consultant)</p> <p>Data collection challenges at national level</p> <ul style="list-style-type: none"> • Albania • Kosovo* • Serbia <p>Emerging trends in new psychoactive substance (NPS) supply and use</p> <ul style="list-style-type: none"> • Developing national early warning system in Serbia: a protocol and situation with NPS • Updates on situation with new psychoactive substances in Bosnia and Herzegovina <p>Discussion</p>
11.00	Coffee break

* This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence.

11.30	<p>Plenary session III: Fostering scientific cooperation on data collection, analysis and interpretation – Prevalence of drug use</p> <p>The General Population Survey (GPS): measuring and understanding drug use</p> <p>Recent GPS in the region</p> <ul style="list-style-type: none"> • Montenegro • Former Yugoslav Republic of Macedonia <p>Discussion</p>
12.30	<p>Plenary session IV: Fostering scientific cooperation on data collection, analysis and interpretation – Monitoring drug treatment systems</p> <p>Treatment mapping and the European Facility Survey Questionnaire (EFSQ): objectives, method and results — Barbara Janíková (External consultant)</p> <p>Comments from the countries</p> <p>Discussion</p>
13.00	Lunch break
14.00	<p>Plenary session V: Development and promotion of the added value of cooperation</p> <p>Presentation of the main highlights of the 2017 European Drug Report (EDR)</p> <p>National reporting</p> <p>Discussion</p>
15.30	Coffee break
16.00	<p>Plenary session VI: Way forward and closing remarks</p> <p>Continuation of activities: presentation of the EMCDDA-IPA6 project — Gonçalo Felgueiras e Sousa (Head of Reitox and external partners unit, EMCDDA)</p> <p>Discussion</p> <p>Conclusions</p>
16.30	End of the meeting